Authors: V M Petriev V K Tishchenko R N Krasikova
Publish Date: 2016/08/12
Volume: 50, Issue: 4, Pages: 209-220
Abstract
This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations RPP based on labeled glucose derivatives Most attention is paid to 218Ffluoro2deoxyDglucose 18FFDG a glucose analog labeled with fluorine18 T 1/2 = 110 min and the only radiotracer for glycolysis which is used in 90 of clinical studies using positron emission tomography PET We describe approaches to the synthesis of 18FFDG and stateoftheart automated technologies allowing tens of clinical doses of RPP for PET investigations of patients to be prepared The main areas of use of PET with 18FFDG in the diagnosis of various tumors are discussed as is the potential for using glucose derivatives with other radionuclides 68Ga 123I 99mTc 188Re as tracers for use in PET and SPECT diagnosis
Keywords: